We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.84%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$546M
AUM Growth
-$31.1M
Cap. Flow
+$46.9M
Cap. Flow %
8.6%
Top 10 Hldgs %
37.26%
Holding
117
New
22
Increased
53
Reduced
27
Closed
15

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$20.3M
2
HCA icon
HCA Healthcare
HCA
+$15.4M
3
COO icon
Cooper Companies
COO
+$9.29M
4
CRL icon
Charles River Laboratories
CRL
+$9.07M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.02M

Top Sells

Rank Stock Value
1
DHR icon
Danaher
DHR
+$14.6M
2
LNTH icon
Lantheus
LNTH
+$14.3M
3
WAT icon
Waters Corp
WAT
+$10.8M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.89M
5
SDGR icon
Schrodinger
SDGR
+$4.59M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Industrials 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$71.5B
$31.5M 5.78%
597,260
+124,155
+26% +$6.51M
UTHR icon
2
United Therapeutics
UTHR
$23.1B
$31.2M 5.72%
138,328
+15,350
+12% +$3.54M
BDX icon
3
Becton Dickinson
BDX
$48.2B
$25.3M 4.64%
97,952
+14,306
+17% +$3.86M
DXCM icon
4
DexCom
DXCM
$32B
$24.8M 4.54%
265,518
+180,392
+212% +$20.3M
COO icon
5
Cooper Companies
COO
$14.5B
$20.8M 3.81%
261,284
+100,792
+63% +$9.29M
COR icon
6
Cencora
COR
$61.2B
$17.4M 3.19%
96,845
+10,595
+12% +$1.96M
THC icon
7
Tenet Healthcare
THC
$21.1B
$14.9M 2.73%
226,141
-27,896
-11% -$2.09M
HCA icon
8
HCA Healthcare
HCA
$89.5B
$13.8M 2.53%
+56,160
New +$15.4M
PCVX icon
9
Vaxcyte
PCVX
$8.64B
$12.1M 2.22%
238,132
+9,627
+4% +$475K
IMGN
10
DELISTED
Immunogen Inc
IMGN
$11.4M 2.09%
717,920
-122,891
-15% -$2.04M
RXST icon
11
RxSight
RXST
$260M
$10.6M 1.95%
381,331
-117,300
-24% -$3.5M
SDGR icon
12
Schrodinger
SDGR
$1.36B
$10.4M 1.91%
368,654
-113,972
-24% -$4.59M
HUM icon
13
Humana
HUM
$46.2B
$10.4M 1.9%
21,311
+10,151
+91% +$4.77M
KROS icon
14
Keros Therapeutics
KROS
$221M
$9.52M 1.74%
298,475
+21,660
+8% +$809K
NBIX icon
15
Neurocrine Biosciences
NBIX
$16.6B
$9.43M 1.73%
83,845
-55,890
-40% -$5.89M
KNSA icon
16
Kiniksa Pharmaceuticals
KNSA
$5.93B
$8.86M 1.62%
509,810
+218,107
+75% +$3.67M
KRTX
17
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$8.68M 1.59%
51,311
+2,078
+4% +$391K
CRL icon
18
Charles River Laboratories
CRL
$12.8B
$8.65M 1.59%
+44,160
New +$9.07M
MNKD icon
19
MannKind Corp
MNKD
$1.32B
$8.54M 1.57%
2,068,947
+252,366
+14% +$1.13M
HAE icon
20
Haemonetics
HAE
$4B
$7.97M 1.46%
88,962
-26,099
-23% -$2.33M
ZBH icon
21
Zimmer Biomet
ZBH
$18.4B
$7.97M 1.46%
+71,000
New +$9.02M
TMO icon
22
Thermo Fisher Scientific
TMO
$220B
$7.76M 1.42%
+15,332
New +$8.17M
DCPH
23
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$7.6M 1.39%
597,403
+24,164
+4% +$333K
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.12B
$7.4M 1.36%
216,644
-1,096
-0.5% -$41K
ACLX
25
DELISTED
Arcellx
ACLX
$7.3M 1.34%
203,482
+8,222
+4% +$283K
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2023 Portfolio in Review

As of Q3 2023, Parkman Healthcare Partners held 117 positions worth $546M, down 5.4% from $577M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Parkman Healthcare Partners deployed $46.9M of net new capital in Q3 2023, opening 22 new positions and adding to 53 existing holdings. Its largest new stake was HCA Healthcare: 56,160 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Lantheus, an estimated $14.3M trimmed.

  • Parkman Healthcare Partners's largest Q3 2023 buy was HCA Healthcare: 56,160 shares worth $13.8M.
  • Parkman Healthcare Partners added most to DexCom in Q3 2023, an estimated $20.3M increase.
  • Parkman Healthcare Partners's biggest Q3 2023 reduction was Lantheus, cutting an estimated $14.3M.
  • Parkman Healthcare Partners fully exited Danaher in Q3 2023, selling an estimated $14.6M.
  • Parkman Healthcare Partners's ten largest holdings make up 37% of its $546M portfolio in Q3 2023.
  • Parkman Healthcare Partners opened 22 new positions and closed 15 in Q3 2023.
  • Parkman Healthcare Partners's portfolio value fell 5.4% quarter-over-quarter to $546M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2023, filed 14 Nov 2023.